EAGLE PHARMACEUTICALS INC's ticker is EGRX and the CUSIP is 269796108. A total of 76 filers reported holding EAGLE PHARMACEUTICALS INC in Q2 2024. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $1,975,466 | -58.0% | 352,762 | -60.7% | 0.00% | – |
| Q1 2024 | $4,704,505 | -8.7% | 897,806 | -8.8% | 0.00% | – |
| Q4 2023 | $5,151,070 | -63.3% | 984,908 | +10.8% | 0.00% | – |
| Q3 2023 | $14,020,777 | -28.6% | 889,079 | -12.0% | 0.00% | -100.0% |
| Q2 2023 | $19,646,784 | -63.1% | 1,010,637 | -46.1% | 0.00% | -50.0% |
| Q1 2023 | $53,224,928 | -2.9% | 1,876,099 | +0.1% | 0.00% | 0.0% |
| Q4 2022 | $54,790,116 | +11.3% | 1,874,448 | +0.6% | 0.00% | 0.0% |
| Q3 2022 | $49,217,000 | -42.8% | 1,862,933 | -3.8% | 0.00% | -33.3% |
| Q2 2022 | $86,078,000 | -12.3% | 1,937,364 | -2.3% | 0.00% | 0.0% |
| Q1 2022 | $98,105,000 | -2.1% | 1,982,333 | +0.7% | 0.00% | 0.0% |
| Q4 2021 | $100,252,000 | -12.2% | 1,968,816 | -3.8% | 0.00% | 0.0% |
| Q3 2021 | $114,143,000 | +28.1% | 2,046,286 | -1.7% | 0.00% | +50.0% |
| Q2 2021 | $89,118,000 | +7.8% | 2,082,183 | +5.1% | 0.00% | 0.0% |
| Q1 2021 | $82,703,000 | -8.5% | 1,981,371 | +2.1% | 0.00% | -33.3% |
| Q4 2020 | $90,393,000 | +11.5% | 1,941,016 | +1.8% | 0.00% | 0.0% |
| Q3 2020 | $81,034,000 | -2.3% | 1,907,601 | +10.3% | 0.00% | 0.0% |
| Q2 2020 | $82,972,000 | +7.9% | 1,729,319 | +3.4% | 0.00% | -25.0% |
| Q1 2020 | $76,899,000 | -29.2% | 1,671,723 | -7.6% | 0.00% | 0.0% |
| Q4 2019 | $108,655,000 | +11.3% | 1,808,512 | +4.8% | 0.00% | 0.0% |
| Q3 2019 | $97,631,000 | +0.6% | 1,725,857 | -1.0% | 0.00% | 0.0% |
| Q2 2019 | $97,089,000 | +15.8% | 1,743,694 | +5.0% | 0.00% | 0.0% |
| Q1 2019 | $83,811,000 | +20.2% | 1,659,972 | -4.1% | 0.00% | 0.0% |
| Q4 2018 | $69,745,000 | -42.2% | 1,731,054 | -0.6% | 0.00% | -20.0% |
| Q3 2018 | $120,753,000 | +11.4% | 1,741,712 | +21.6% | 0.01% | 0.0% |
| Q2 2018 | $108,351,000 | +64.7% | 1,432,090 | +14.7% | 0.01% | +66.7% |
| Q1 2018 | $65,800,000 | -0.1% | 1,248,803 | +1.3% | 0.00% | 0.0% |
| Q4 2017 | $65,835,000 | -12.5% | 1,232,398 | -2.3% | 0.00% | -25.0% |
| Q3 2017 | $75,241,000 | -20.4% | 1,261,585 | +5.2% | 0.00% | -20.0% |
| Q2 2017 | $94,578,000 | -5.5% | 1,198,879 | -0.7% | 0.01% | 0.0% |
| Q1 2017 | $100,097,000 | +192394.2% | 1,206,853 | +183871.5% | 0.01% | – |
| Q4 2016 | $52,000 | -3.7% | 656 | -15.5% | 0.00% | – |
| Q3 2016 | $54,000 | +92.9% | 776 | +7.6% | 0.00% | – |
| Q2 2016 | $28,000 | +33.3% | 721 | +43.3% | 0.00% | – |
| Q1 2016 | $21,000 | +23.5% | 503 | +163.4% | 0.00% | – |
| Q4 2015 | $17,000 | +21.4% | 191 | 0.0% | 0.00% | – |
| Q3 2015 | $14,000 | -92.3% | 191 | -91.6% | 0.00% | – |
| Q2 2015 | $183,000 | – | 2,264 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Hudson Executive Capital LP | 1,623,554 | $90,400,000 | 4.35% |
| Park West Asset Management LLC | 1,300,000 | $72,384,000 | 3.01% |
| Smith, Graham & Co., Investment Advisors, LP | 153,674 | $8,557,000 | 0.92% |
| Matarin Capital Management, LLC | 202,652 | $11,284,000 | 0.81% |
| Capital Impact Advisors, LLC | 35,149 | $1,933,000 | 0.71% |
| CHARTWELL INVESTMENT PARTNERS, LLC | 196,759 | $10,956,000 | 0.36% |
| Stanley-Laman Group, Ltd. | 24,000 | $1,336,000 | 0.32% |
| PDT Partners, LLC | 55,100 | $3,068,000 | 0.18% |
| Quantinno Capital Management LP | 5,308 | $296,000 | 0.17% |
| Foundry Partners, LLC | 73,385 | $4,086,000 | 0.16% |